<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267967</url>
  </required_header>
  <id_info>
    <org_study_id>2014-012-00CH1</org_study_id>
    <nct_id>NCT02267967</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors</brief_title>
  <official_title>A Multi-Center, Open-Label, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Sufatinib in Treating Advanced Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      a multicenter, open-label phase Ib study to determine the safety, tolerability and&#xD;
      preliminary efficacy of Sulfatinib 300 mg once a day in treating advanced neuroendocrine&#xD;
      tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population is patients with low- or intermediate-grade (G1 or G2) advanced NET who&#xD;
      have failed in standard treatment or are unable to receive standard treatment.Sulfatinib 300&#xD;
      mg once a day (QD) will be orally administrated on a 28-day cycle. Investigators will&#xD;
      evaluate the clinical tumor response to Sulfatinib, and if investigators determine that the&#xD;
      patient can benefit from the continuation of treatment, the patient will continue the&#xD;
      Sulfatinib treatment. The duration of study will be 2 years. At the time of study completion,&#xD;
      if investigators believe patients can continue to benefit from the investigational product,&#xD;
      patients may be provided with Sulfatinib with the agreement of the sponsor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2014</start_date>
  <completion_date type="Actual">August 23, 2017</completion_date>
  <primary_completion_date type="Actual">August 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of AE/SAEs</measure>
    <time_frame>from day 1 of first dosing to 30 days after permanent discontinuation of Sulfatinib</time_frame>
    <description>the safety of Sulfatinib</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Sulfatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfatinib</intervention_name>
    <description>Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.</description>
    <arm_group_label>Sulfatinib</arm_group_label>
    <other_name>HMPL-012</other_name>
    <other_name>Surufatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fully understand the study and voluntarily sign the informed consent form;&#xD;
&#xD;
          2. Be at least 18 years old;&#xD;
&#xD;
          3. Have a confirmed histological or cytological diagnosis of low- or intermediate-grade&#xD;
             advanced NETs (unresectable or metastatic), for which standard treatment has failed or&#xD;
             cannot be received. The NETs must meet the following criteria: (a) be GEP-NETs or NETs&#xD;
             with the primary lesion located in tissue other than the lung or thymus (including&#xD;
             unknown primary lesion location), with a mitotic count of ≤ 20/10 High Power Field&#xD;
             [HPF] and a Ki67 index of ≤ 20%; or (b) be NETs of the lung or thymus (carcinoid) with&#xD;
             a mitotic count of ≤ 10/10 High Power Field [HPF])&#xD;
&#xD;
          4. Have measurable lesions (according to RECIST 1.1);&#xD;
&#xD;
          5. Have a performance status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group&#xD;
             (ECOG) scale;&#xD;
&#xD;
          6. Have expected survival of more than 12 weeks;&#xD;
&#xD;
          7. Female patients with reproductive potential must agree to use an effective&#xD;
             contraceptive method, for example, double-barrier device, condom, oral or injection&#xD;
             birth control medication or intrauterine device, during the study and for 90 days&#xD;
             after study completion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Absolute neutrophil count (ANC) of &lt; 1.5×109/L, or platelet count of &lt; 100 ×109/L, or&#xD;
             hemoglobin &lt; 9 g/dL;&#xD;
&#xD;
          2. Serum total bilirubin &gt; 1.5 times the upper limit of normal (ULN);&#xD;
&#xD;
          3. ALT, AST or ALP &gt; 2.5 ULN without hepatic metastases or ALT, AST or ALP &gt; 5 ULN with&#xD;
             hepatic metastases&#xD;
&#xD;
          4. Clinically significant serum potassium (regardless of potassium agent&#xD;
             supplementation); serum calcium (ionic or binding to albumin post-adjusted) or&#xD;
             clinically significant abnormal serum magnesium (regardless of magnesium agent&#xD;
             supplementation);&#xD;
&#xD;
          5. Serum creatinine &gt; 1.5 ULN (with the exception of CCR ≥ 60 ml/min based on 24-hour&#xD;
             urine collection);&#xD;
&#xD;
          6. Urine protein &gt; 2+, or 24-hour urine protein quantity &gt;1 gram;&#xD;
&#xD;
          7. Uncontrolled hypertension, defined as: systolic blood pressure ≥ 140 mmHg or diastolic&#xD;
             blood pressure ≥ 90mmHg;&#xD;
&#xD;
          8. International Normalized Ratio (INR) &gt; 1.5 ULN or activated partial thromboplastin&#xD;
             time (aPTT) &gt; 1.5 ULN. INR is only for patients not receiving anticoagulant therapy;&#xD;
&#xD;
          9. History or presence of digestive tract diseases, including active gastric/duodenal&#xD;
             ulcer or ulcerative colitis, or active hemorrhage of an unresected gastrointestinal&#xD;
             tumor, or an evaluation by investigators of having any other condition that could&#xD;
             possibly result in gastrointestinal tract hemorrhage or perforation;&#xD;
&#xD;
         10. History or presence of serious hemorrhage (&gt; 30 ml within 3 months), hemoptysis (&gt; 5&#xD;
             ml fresh blood within 4 weeks) or a thromboembolic event (including transient ischemic&#xD;
             attack) within 12 months;&#xD;
&#xD;
         11. Clinically significant cardiovascular disease, including but not limited to, acute&#xD;
             myocardial infarction within 6 months prior to enrolment, severe/unstable angina&#xD;
             pectoris or coronary artery bypass grafting, New York Heart Association Class III/IV&#xD;
             congestive heart failure, ventricular arrhythmias requiring treatment or left&#xD;
             ventricular ejection fraction (LVEF) &lt; 50%;&#xD;
&#xD;
         12. Other malignancies within the previous 5 years, with the exception of basal cell&#xD;
             carcinoma, squamous-cell carcinoma post radical resection, or cervical carcinoma in&#xD;
             situ;&#xD;
&#xD;
         13. Anti-tumor therapies within 4 weeks prior to the initiation of investigational&#xD;
             treatment, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy&#xD;
             and immunotherapy;&#xD;
&#xD;
         14. Palliative radiotherapy for a bone metastasis lesion within 2 weeks prior to the&#xD;
             initiation of investigational treatment;&#xD;
&#xD;
         15. Surgery prior to enrolment within 28 days prior to the initiation of investigational&#xD;
             treatment or unhealed surgical incision;&#xD;
&#xD;
         16. Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1&#xD;
             (except for hair loss);&#xD;
&#xD;
         17. Clinically significant active infection;&#xD;
&#xD;
         18. Human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
         19. History of clinically significant hepatic diseases, including viral hepatitis,&#xD;
             (Hepatitis B carriers with active HBV infection, i.e., HBV DNA positive [&gt;1×104/ml];&#xD;
             Hepatitis C virus infection with HBV RNA positive [&gt;1×103/ml]); or other types of&#xD;
             hepatitis, and liver cirrhosis.&#xD;
&#xD;
         20. Women who are pregnant or lactating;&#xD;
&#xD;
         21. Brain metastases and/or spinal cord compression untreated with surgery and/or&#xD;
             radiotherapy, and without clinical imaging evidence of disease stability of longer&#xD;
             than 14 days;&#xD;
&#xD;
         22. Inability to orally take medicine, dysphagia or an active gastric ulcer resulting from&#xD;
             previous surgery or a severe gastrointestinal disease, or any other condition that&#xD;
             investigators believe may affect absorption of the investigational product;&#xD;
&#xD;
         23. Receive investigational treatment in another clinical study within the 4 weeks prior&#xD;
             to enrolment;&#xD;
&#xD;
         24. Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory&#xD;
             result, or any other condition that investigators suspect may prohibit use of the&#xD;
             investigational product, affect interpretation of study results, or put the patient at&#xD;
             high risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison Medi Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the 307 Hospital of People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610047</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

